COVID-19 fulminant myocarditis: a case report

COVID-19 fulminant myocarditis: a case report
复制标题

DOI:
10.1093/ehjcr/ytaa212
复制
发表时间:
2020-10-01
影响因子:
1
通讯作者:
Plata-Mosquera, Carlos Andres
Plata-Mosquera, Carlos Andres
中科院分区:
其他
文献类型:
--
作者:
Bernal-Torres, Wikler;Herrera-Escandon, Alvaro;Plata-Mosquera, Carlos Andres

文献摘要

被引文献

相似文献

背景暴发性心肌炎是一种致死率高、并发症多的灾难性疾病。一个病毒的病因是常见的和SARS-CoV-2的含义尚不清楚。Case summary一个38岁的女人谁最近从西班牙抵达与心悸,突然开始3天前介绍,并与血液动力学不稳定,没有呼吸困难或胸痛。我们在心电图上发现了心肌心包炎的特征,在超声心动图上发现了严重的收缩功能障碍。胸部断层扫描显示结果表明COVID-19感染,SARS-CoV-2的PCR呈阳性。心脏磁共振图像显示心肌炎的露易丝湖标准。该患者接受了免疫调节、类固醇和免疫球蛋白治疗,临床反应良好。讨论该病例的重要性在于强调了一名年轻患者的严重心脏受累,既往无风险因素,COVID-19阳性,以及对药物治疗的良好反应。
Background Fulminant myocarditis is a catastrophic disease with high mortality and complications. A viral aetiology is frequent and the implication of SARS-CoV-2 is not yet known.Case summary A 38-year-old woman who recently arrived from Spain presented with palpitations that started suddenly 3 days prior to presentation and were associated with haemodynamic instability, without dyspnoea or chest pain. We found features of myopericarditis on the electrocardiogram and severe systolic dysfunction on the echo-cardiogram. The chest tomography showed findings which suggested COVID-19 infection, and PCR for SARS-CoV-2 was positive. The cardiac magnetic resonance image showed Lake Louise criteria for myocarditis. The patient was treated with immunomodulatory, steroid, and immunoglobulin therapy, with a favourable clinical response.Discussion The importance of this case lies in highlighting the severe cardiac involvement in a young patient, without previous risk factors, positive for COVID-19, and the favourable response to the medical treatment given.